Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Zerbaxa

Chemical Nameceftolozane/tazobactam
Dosage FormInjection (intravenous; ceftolozane/tazobactam: 1 g/0.5 g)
Drug ClassInhibitors
SystemUrinary, Respiratory
CompanyMerck & Co.
Approval Year2014

Indication

  • Indicated in combination with metronidazole in patients 18 years or older for the treatment of complicated intra-abdominal infections (cIAI) caused by designated susceptible microorganisms.
  • Indicated in patients 18 years or older for the treatment of complicated urinary tract infections (cUTI) (including pyelonephritis) caused by designated susceptible microorganisms.
  • Indicated in patients 18 years or older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by designated susceptible microorganisms.
Last updated on 7/13/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zerbaxa (ceftolozane/tazobactam) Prescribing Information.2022Merck Sharp & Dohme LLC, Rahway, NJ
Document TitleYearSource
Assessment report: Zerbaxa. 2019EMA
Document TitleYearSource
Choosing optimal antibiotics for the treatment of patients infected with Enterobacteriaceae: a network meta-analysis and cost-effectiveness analysis.2021Frontiers in Pharmacology
Real-world use of ceftolozane/tazobactam: a systematic literature review.2021Antimicrobial Resistance and Infection Control
Systematic review of the stability of antimicrobial agents in elastomeric devices for outpatient parenteral antimicrobial therapy services based on NHS Yellow Cover Document standards.2021European Journal of Hospital Pharmacy
The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections—A meta-analysis of randomized controlled trials.2020International Journal of Antimicrobial Agents
Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis.2020International Journal of Antimicrobial Agents